- May 10, 2022
- 2:00 PM - 3:00 PM ET
- Organized By:
Sponsored by the U.S. Food & Drug Administration (FDA)
Annie Ellis, Ovarian Cancer Survivor| Research Advocate
Gwynn Ison, MD, Acting Team Leader, Division of Oncology 1, Office of Oncologic Diseases, Office of New Drugs, CDER
Clara MacKay, MA, Chief Executive Officer, World Ovarian Cancer Coalition
Tracy Moore, LCSW, Oncology Social Worker, Patient Support (Consultant), Ovarian Cancer Research Alliance
Richard Pazdur, MD, Director, Oncology Center of Excellence, FDA
Kimberly Richardson, Ovarian Cancer Survivor | Research Advocate, Black Cancer Collaborative
Moderator: Rea Blakey, Associate Director for External Outreach and Engagement, Oncology Center of Excellence, FDA
Registration required to attend: https://www.surveymonkey.com/r/ZCJTDHT
The Oncology Center of Excellence Conversations On Cancer public panel discussion series is observing World Ovarian Cancer Day. Join this 1-hour informal panel discussion exploring personal perspectives from survivors, clinicians, and patient advocates on the impact of ovarian cancer. Panelists will discuss global challenges of ovarian cancer drug development, address the importance of clinical trial participation, and discuss barriers for patients’ access to clinical trials.
The discussion will also address successful strategies in educating, recruiting and following up with patients about clinical trials. Other discussion topics will include defining clinical benefit and tolerability of new cancer therapies for maintenance treatment of ovarian cancer, when patients receive a treatment to help keep cancer from coming back after it has disappeared following the initial therapy.
A free-of-charge webcast of this public panel discussion will be provided. Registration for the webcast is required at the link above.
FDA plans to post archived webcasts of the Conversations on Cancer program at: https://www.fda.gov/about-fda/oncology-center-excellence/conversations-cancer
For any inquiries regarding this program, please send an email to: OCE-Engagement@fda.hhs.gov